| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/12/2011 | WO2011057148A1 Compounds and compositions as tlr-7 activity modulators |
| 05/12/2011 | WO2011057145A2 Imidazo[1,2-a] pyridine compounds, synthesis thereof, and methods of using same |
| 05/12/2011 | WO2011057132A1 Methods for obtaining bioactive compounds from phytoplankton |
| 05/12/2011 | WO2011057129A2 Compositions and methods for stimulating hair growth |
| 05/12/2011 | WO2011057121A1 Compositions and methods for treating colitis |
| 05/12/2011 | WO2011057115A1 Prolyl hydroxylase inhibitors |
| 05/12/2011 | WO2011057112A1 Methods for increasing the stabilization of hypoxia inducible factor-1 alpha |
| 05/12/2011 | WO2011057110A1 Gpr109a agonists for the treatment of cerebral ischemia |
| 05/12/2011 | WO2011057108A1 Ophthalmic formulations containing substituted gamma lactams and methods for use thereof |
| 05/12/2011 | WO2011057082A2 A method to enhance endurance |
| 05/12/2011 | WO2011057060A2 Copper salts of ion exchange materials for use in the treatment and prevention of infections |
| 05/12/2011 | WO2011057054A1 Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline |
| 05/12/2011 | WO2011057022A1 Compounds and methods for kinase modulation, and indications therefor |
| 05/12/2011 | WO2011056978A2 S isomers of alpha-methyl hydrocinnamic acid for the treatment of blood disorders |
| 05/12/2011 | WO2011056957A2 Enzyme inhibiting compounds |
| 05/12/2011 | WO2011056939A1 Process for the preparation of imidazo[2,1-b][1,3]benzothiazole derivatives |
| 05/12/2011 | WO2011056930A2 Fragile x mental retardation protein (fmrp), compositions, and methods related thereto |
| 05/12/2011 | WO2011056916A1 Tryptophan hydroxylase inhibitors for the treatment of cancer |
| 05/12/2011 | WO2011056883A1 Lipid formulated compositions and methods for inhibiting expression of transthyretin (ttr) |
| 05/12/2011 | WO2011056871A2 Rhamnolipid mechanism |
| 05/12/2011 | WO2011056849A1 Methods of treating elevations in mtor signaling |
| 05/12/2011 | WO2011056806A1 Process for the preparation of pyrazinone thrombin inhibitor and its intermediates |
| 05/12/2011 | WO2011056793A2 Composition, method, and kit for alpha-1 proteinase inhibitor |
| 05/12/2011 | WO2011056788A2 Inhibiting neurotransmitter reuptake |
| 05/12/2011 | WO2011056773A2 Inhibiting neurotransmitter reuptake |
| 05/12/2011 | WO2011056764A1 Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles |
| 05/12/2011 | WO2011056759A2 Oral compositions for treatment of dry mouth |
| 05/12/2011 | WO2011056744A1 IRE-1 α INHIBITORS |
| 05/12/2011 | WO2011056740A1 Quinazoline compounds |
| 05/12/2011 | WO2011056739A1 Compounds and methods |
| 05/12/2011 | WO2011056725A1 Pyridine derivatives and methods of use thereof |
| 05/12/2011 | WO2011056703A1 Nutraceutical composition and methods for preventing or treating multiple sclerosis |
| 05/12/2011 | WO2011056702A2 Fast dissolving/disintegrating coating compositions |
| 05/12/2011 | WO2011056667A2 Rosacea topical skin treatment method and formulation |
| 05/12/2011 | WO2011056653A2 Clonidine formulations having antimicrobial properties |
| 05/12/2011 | WO2011056652A1 Imidazole derivatives as ido inhibitors |
| 05/12/2011 | WO2011056650A2 Methods and compositions for treating and preventing viral infections |
| 05/12/2011 | WO2011056647A1 Deuterated 5,6-dihydro-1h-pyridin-2-one compounds |
| 05/12/2011 | WO2011056635A1 Benzimidazoles as fatty acid synthase inhibitors |
| 05/12/2011 | WO2011056630A2 Small molecule inhibitors of hepatitis c virus |
| 05/12/2011 | WO2011056604A2 Treatment of sunburn using analgesics and antihistamines |
| 05/12/2011 | WO2011056599A2 Caged ceramide-1-phosphate derivatives |
| 05/12/2011 | WO2011056589A1 Bisphosphonate compounds for treating bone metabolism disorders |
| 05/12/2011 | WO2011056573A1 Azabicyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands |
| 05/12/2011 | WO2011056566A2 Compounds and methods for treatment of cancer |
| 05/12/2011 | WO2011056549A1 Molecular targets and dietary modulators of exercise-induced muscle damage |
| 05/12/2011 | WO2011056545A2 Antimicrobial ionic liquids |
| 05/12/2011 | WO2011056542A1 Cancer therapy with combinations of fts with hdac inhibitors |
| 05/12/2011 | WO2011056532A2 Bazedoxifene formulations with antioxidants |
| 05/12/2011 | WO2011056511A2 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase |
| 05/12/2011 | WO2011056503A1 Azabicyclo[2.2.1] heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands |
| 05/12/2011 | WO2011056486A2 Devices, methods, and composition for controlling infections |
| 05/12/2011 | WO2011056477A2 Methods for treating inflammation and oxidative stress related diseases |
| 05/12/2011 | WO2011056440A1 Heterocyclic compounds as ccr1 receptor antagonists |
| 05/12/2011 | WO2011056382A1 Angiogenesis promoted by caged growth factors |
| 05/12/2011 | WO2011056325A2 Oligomer-calcimimetic conjugates and related compounds |
| 05/12/2011 | WO2011056222A1 Methods of treating disorders associated with protein aggregation |
| 05/12/2011 | WO2011056174A1 Migraine headache relief composition |
| 05/12/2011 | WO2011056168A1 Antimicrobial compositions and methods |
| 05/12/2011 | WO2011056126A1 Novel 1,3-oxazolidine compounds and their use as renin inhibitors |
| 05/12/2011 | WO2011056021A2 Use of benzo-heterocycle derivatives for preventing and treating cancer or for inhibiting cancer metastasis |
| 05/12/2011 | WO2011055965A2 Methods for treating attention-deficit/hyperactivity disorder |
| 05/12/2011 | WO2011055944A2 Methods for treating fibromyalgia syndrome |
| 05/12/2011 | WO2011055917A2 Arginine derivatives or salts thereof exhibiting the effects of improving sexual function, composition for improving sexual function comprising same, and method for preparing same |
| 05/12/2011 | WO2011055888A1 Nanoparticle-based gene delivery systems |
| 05/12/2011 | WO2011055843A1 Retinoid compound |
| 05/12/2011 | WO2011055838A1 Compound for inhibiting biosynthesis of testosterone |
| 05/12/2011 | WO2011055810A1 Dihydro pyrroloquinoline derivatives |
| 05/12/2011 | WO2011055770A1 Fused heterocyclic compound |
| 05/12/2011 | WO2011055708A1 Isopropyl methyl phenol-containing liquid composition for oral cavity |
| 05/12/2011 | WO2011055561A1 Protein crosslinking inhibitor and use thereof |
| 05/12/2011 | WO2011055391A1 Substituted fused pyrimidine compounds, its preparation and uses thereof |
| 05/12/2011 | WO2011055385A1 Modified release formulation of lacosamide |
| 05/12/2011 | WO2011055383A2 Intranasal delivery to improve the performance of children suffering from dyslexia |
| 05/12/2011 | WO2011055379A1 A stable injectable pharmaceutical composition of aceclofenac and process for preparing thereof |
| 05/12/2011 | WO2011055377A1 A novel process for the preparation of prostaglandins and intermediates thereof |
| 05/12/2011 | WO2011055375A1 Bioequivalent formulation of efavirenz |
| 05/12/2011 | WO2011055320A1 Imidazopyridine derivatives |
| 05/12/2011 | WO2011055303A1 Tablet formulations of neratinib maleate |
| 05/12/2011 | WO2011055270A1 Indole based receptor crth2 antagonists |
| 05/12/2011 | WO2011055269A1 Delivery carrier |
| 05/12/2011 | WO2011055247A1 A synthetic cyclic dipeptide and a process thereof |
| 05/12/2011 | WO2011055215A2 Novel kinase modulators |
| 05/12/2011 | WO2011055165A1 Composition comprising a phosphate, a phosphonate, a phosphite or a phosphoramidate with polyol substructures |
| 05/12/2011 | WO2011055142A2 1,4-quinones and their sulfur analogues useful as ligands of n-acetyltransferases |
| 05/12/2011 | WO2011055115A1 Akt / pkb inhibitors |
| 05/12/2011 | WO2011055083A2 Multilayer pharmaceutical composition that can be dispersed in water and which contains a combination of antimalarial agents |
| 05/12/2011 | WO2011054990A2 Compositions for inhibiting and/or blocking epithelial-mesenchymal transition |
| 05/12/2011 | WO2011054947A1 Thiadiazolidinedioxide p2x7 receptor antagonists |
| 05/12/2011 | WO2011054944A1 Use of lutein containing compositions to improve certain aspects of memory |
| 05/12/2011 | WO2011054939A2 Compositions and methods for inhibiting expression of kif10 genes |
| 05/12/2011 | WO2011054922A1 Salts of fused pyrazine compounds, useful for the treatment of degenerative and inflammatory diseases. |
| 05/12/2011 | WO2011054888A1 4r,5s-enantiomer of 2-(5-methyl-2-oxo-4-phenyl-pyrrolidin-1-yl)-acetamide with nootropic activity |
| 05/12/2011 | WO2011054885A1 1-substituted 2-azabicyclo [3.1.1] heptyl derivatives useful as nicotinic acetylcholine receptor modulators for treating neurologic disorders |
| 05/12/2011 | WO2011054875A1 Pharmaceuticals containing choline |
| 05/12/2011 | WO2011054848A1 Thetrahydroquinolines derivatives as bromodomain inhibitors |
| 05/12/2011 | WO2011054846A1 Imidazo [4, 5-c] quinoline derivates as bromodomain inhibitors |
| 05/12/2011 | WO2011054845A1 Benzodiazepine bromodomain inhibitor |
| 05/12/2011 | WO2011054844A1 Condensed azepine derivatives as bromodomain inhibitors |
| 05/12/2011 | WO2011054843A1 Bromodomain inhibitors for treating autoimmune and inflammatory diseases |